Published in Pharmacol Res on August 05, 2010
Emerging support for a role of exercise in attention-deficit/hyperactivity disorder intervention planning. Curr Psychiatry Rep (2012) 0.92
Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments. Behav Brain Res (2013) 0.88
Juvenile methylphenidate reduces prefrontal cortex plasticity via D3 receptor and BDNF in adulthood. Front Synaptic Neurosci (2014) 0.86
Aberrant striatal dopamine transmitter dynamics in brain-derived neurotrophic factor-deficient mice. J Neurochem (2011) 0.84
Serum brain-derived neurotrophic factor (BDNF) levels in attention deficit-hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry (2013) 0.84
Adolescent methylphenidate treatment differentially alters adult impulsivity and hyperactivity in the Spontaneously Hypertensive Rat model of ADHD. Pharmacol Biochem Behav (2015) 0.81
Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine. Psychopharmacology (Berl) (2013) 0.78
Prefrontal cortical and striatal transcriptional responses to the reinforcing effect of repeated methylphenidate treatment in the spontaneously hypertensive rat, animal model of attention-deficit/hyperactivity disorder (ADHD). Behav Brain Funct (2014) 0.77
Dynamic modulation of basic Fibroblast Growth Factor (FGF-2) expression in the rat brain following repeated exposure to cocaine during adolescence. Psychopharmacology (Berl) (2012) 0.76
Stress and cocaine interact to modulate Arc/Arg3.1 expression in rat brain. Psychopharmacology (Berl) (2011) 0.76
Preventative treatment in an animal model of ADHD: Behavioral and biochemical effects of methylphenidate and its interactions with ovarian hormones in female rats. Eur Neuropsychopharmacol (2016) 0.75
BDNF concentrations and daily fluctuations differ among ADHD children and respond differently to methylphenidate with no relationship with depressive symptomatology. Psychopharmacology (Berl) (2016) 0.75
Mind-Body Therapy for Children with Attention-Deficit/Hyperactivity Disorder. Children (Basel) (2017) 0.75
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology (2004) 3.52
Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry (2010) 1.70
Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol Pharmacol (2008) 1.61
Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev (2006) 1.51
MCP-1 gene (SCYA2) and schizophrenia: a case-control association study. Am J Med Genet B Neuropsychiatr Genet (2005) 1.51
BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. Eur Arch Psychiatry Clin Neurosci (2011) 1.50
Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.50
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci (2009) 1.48
Neuronal plasticity: a link between stress and mood disorders. Psychoneuroendocrinology (2009) 1.47
Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. Am J Hum Genet (2012) 1.47
Noradrenaline in mood and anxiety disorders: basic and clinical studies. Int Clin Psychopharmacol (2003) 1.34
Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions. Biol Psychiatry (2004) 1.32
Stress during development: Impact on neuroplasticity and relevance to psychopathology. Prog Neurobiol (2007) 1.31
Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology (2011) 1.31
Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology (2012) 1.28
Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci (2005) 1.25
Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. Proc Natl Acad Sci U S A (2013) 1.23
Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades. Neuropsychopharmacology (2004) 1.23
New copy number variations in schizophrenia. PLoS One (2010) 1.22
Repeated exposure to cocaine differently modulates BDNF mRNA and protein levels in rat striatum and prefrontal cortex. Eur J Neurosci (2007) 1.17
Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS One (2010) 1.16
Glucocorticoid-related molecular signaling pathways regulating hippocampal neurogenesis. Neuropsychopharmacology (2012) 1.16
Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology (2007) 1.10
Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol (2012) 1.08
Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol (2006) 1.06
Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs. Biol Psychiatry (2006) 1.05
Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress: modulation by antidepressant treatment. Neuropsychopharmacology (2012) 1.04
Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol Psychiatry (2002) 1.03
Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry (2011) 1.02
VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry (2008) 1.02
Acute stress responsiveness of the neurotrophin BDNF in the rat hippocampus is modulated by chronic treatment with the antidepressant duloxetine. Neuropsychopharmacology (2008) 1.02
Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun (2012) 1.02
Serum brain-derived neurotrophic factor levels in different neurological diseases. Biomed Res Int (2013) 1.01
Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol Psychiatry (2004) 1.00
Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. J Affect Disord (2006) 1.00
Depression pathogenesis and treatment: what can we learn from blood mRNA expression? BMC Med (2013) 0.98
Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimers Dement (2009) 0.98
Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. J Am Acad Child Adolesc Psychiatry (2012) 0.98
Atypical dementia associated with a novel presenilin-2 mutation. Ann Neurol (2003) 0.97
Reduced neuroplasticity in aged rats: a role for the neurotrophin brain-derived neurotrophic factor. Neurobiol Aging (2013) 0.97
Prenatal stress elicits regionally selective changes in basal FGF-2 gene expression in adulthood and alters the adult response to acute or chronic stress. Neurobiol Dis (2005) 0.96
Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacology (2007) 0.96
Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. Int J Neuropsychopharmacol (2009) 0.96
Alterations of brain-derived neurotrophic factor serum levels in patients with alcohol dependence. Alcohol Clin Exp Res (2011) 0.95
Repeated stress prevents cocaine-induced activation of BDNF signaling in rat prefrontal cortex. Eur Neuropsychopharmacol (2009) 0.94
Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis. J Neurochem (2011) 0.94
Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients: a case-control study. J Affect Disord (2009) 0.93
The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology (2010) 0.93
Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox Res (2009) 0.93
Dynamic regulation of fibroblast growth factor 2 (FGF-2) gene expression in the rat brain following single and repeated cocaine administration. J Neurochem (2006) 0.93
Corticostriatal brain-derived neurotrophic factor dysregulation in adult rats following prenatal stress. Eur J Neurosci (2004) 0.92
Developmental influence of the serotonin transporter on the expression of npas4 and GABAergic markers: modulation by antidepressant treatment. Neuropsychopharmacology (2011) 0.92
Long-Term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms. Mol Pharmacol (2010) 0.92
Interplay between the pro-oxidant and antioxidant systems and proinflammatory cytokine levels, in relation to iron metabolism and the erythron in depression. Free Radic Biol Med (2013) 0.92
Modulation of synaptic plasticity by stress and antidepressants. Bipolar Disord (2002) 0.92
Risk prediction for clinical phenotype in myotonic dystrophy type 1: data from 2,650 patients. Genet Test (2007) 0.92
Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants. BMC Neurosci (2009) 0.91
Single session of cocaine intravenous self-administration shapes goal-oriented behaviours and up-regulates Arc mRNA levels in rat medial prefrontal cortex. Int J Neuropsychopharmacol (2008) 0.91
Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration. Neurobiol Aging (2010) 0.91
Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther (2009) 0.91
Remodelling by early-life stress of NMDA receptor-dependent synaptic plasticity in a gene-environment rat model of depression. Int J Neuropsychopharmacol (2008) 0.91
Stress-induced changes of hippocampal NMDA receptors: modulation by duloxetine treatment. PLoS One (2012) 0.91
Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions. Int J Neuropsychopharmacol (2005) 0.90
Chronic antidepressants induce redistribution and differential activation of alphaCaM kinase II between presynaptic compartments. Neuropsychopharmacology (2007) 0.90
Association between the c. 2495 A>G ATP7B Polymorphism and Sporadic Alzheimer's Disease. Int J Alzheimers Dis (2011) 0.90
Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease. Neurosci Lett (2004) 0.90
Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. Neurogenetics (2008) 0.90